Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAMHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 25.00 +0.91%
BEAM stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.56B
- EPS (TTM)
- -$0.68
- Dividend yield
- None
- 52-week range
- 20.23 – 38.26
- Day range
- 24.45 – 25.37
- Volume / Avg
- 2.34M / 1.94M
- Beta
- —
- Shares outstanding
- 103.29M
- Next earnings
- Nov 3, 2026
52-week range
BEAM stock today
Shares of Beam Therapeutics (BEAM) finished lower on Oct 7 at $24.77, a drop of 1.82% or $0.46 per share, versus the S&P 500's 0.22% decline. Shares are 35.3% below their 52-week high of $38.26, set on Jul 7, 2026 and 22.4% above the 52-week low of $20.23, in the middle of the past year's range. BEAM is down 10.6% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 1.4%.
Beam Therapeutics has posted a net loss over the last twelve months (EPS of -$0.68), so its P/E ratio is not meaningful. Beam Therapeutics's next earnings report is expected on Nov 3, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Beam Therapeutics
Company profileBeam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. John M. Evans M.B.A.
- Headquarters
- Cambridge, MA
- Employees
- 540
- IPO year
- 2020
- Website
- beamtx.com
Analyst forecast
ForecastConsensus (15 analysts)
strong_buy
Avg. price target
$52.15+110.54%
- Strong buy 1
- Buy 12
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 3, 2026
- EPS estimate
- $-1.16
Beam Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RXRXRecursion Pharmaceuticals Inc. Class A | 4.27 | -7.78% | $2.29B | vs BEAM |
| ADMAADMA Biologics Inc | 10.14 | -0.39% | $2.27B | vs BEAM |
| DNLIDenali Therapeutics Inc. | 19.16 | -0.62% | $3.06B | vs BEAM |
| BCRXBioCryst Pharmaceuticals Inc. | 8.40 | +5.66% | $2.15B | vs BEAM |
| ALVOAlvotech | 5.85 | -4.72% | $2.09B | vs BEAM |
| VCELVericel Corporation | 40.74 | +1.72% | $2.09B | vs BEAM |
| VIRVir Biotechnology Inc. | 11.52 | -0.69% | $1.95B | vs BEAM |
| NVAXNovavax Inc. | 11.22 | -0.88% | $1.85B | vs BEAM |
Indexes, lists and sector
Beam Therapeutics stock FAQ
What is Beam Therapeutics's stock price today?
BEAM last traded at $24.77 as of Oct 7, 4:00 PM EDT, down 1.82% on the day. Prices are delayed at least 15 minutes.
When is Beam Therapeutics's next earnings date?
Beam Therapeutics is expected to report earnings on Tuesday, November 3, 2026. Analysts expect EPS of $-1.16.
Who is Beam Therapeutics's CEO?
Mr. John M. Evans M.B.A. is the chief executive officer of Beam Therapeutics Inc., which has about 540 employees.
What is the BEAM 52-week high?
The 52-week high for BEAM is $38.26 and the 52-week low is $20.23. The stock is currently 35.3% below its high.